title: Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
abstract: OBJECTIVE
  To test the hypothesis that in survivors of myocardial infarction, the suppression of ventricular premature depolarizations improves survival free of cardiac arrest and arrhythmic death.
  
  
  METHODS
  International, prospective, multicenter, randomized, placebo-controlled trial.
  
  
  METHODS
  University and community hospitals.
  
  
  METHODS
  A total of 3549 patients with myocardial infarction and left ventricular dysfunction.
  
  
  METHODS
  Administration of encainide, flecainide, moricizine, or placebo to suppress ventricular premature depolarizations.
  
  
  METHODS
  Overall survival and survival free of cardiac arrest or arrhythmic death were compared in patients randomized to long-term, active antiarrhythmic drug therapy vs corresponding placebo, using the stratified log rank statistic.
  
  
  RESULTS
  At 1 year from the time of randomization to blinded therapy, 95% of placebo-treated patients vs 90% of active drug-treated patients remained alive (P = .0006). Similarly, at 1 year, 96% of placebo-treated patients vs 93% of active drug-treated patients remained free of cardiac arrest or arrhythmic death (P = .003).
  
  
  CONCLUSIONS
  The suppression of asymptomatic or mildly symptomatic ventricular arrhythmias after myocardial infarction does not improve survival and can increase mortality. Treatment strategies designed solely to suppress these arrhythmias should no longer be followed.
authors.affiliation: Department of Medicine, University of Alabama at Birmingham.
authors.forename: A E
authors.initials: AE
authors.lastname: Epstein
authors.forename: A P
authors.initials: AP
authors.lastname: Hallstrom
authors.forename: W J
authors.initials: WJ
authors.lastname: Rogers
authors.forename: P R
authors.initials: PR
authors.lastname: Liebson
authors.forename: A A
authors.initials: AA
authors.lastname: Seals
authors.forename: J L
authors.initials: JL
authors.lastname: Anderson
authors.forename: J D
authors.initials: JD
authors.lastname: Cohen
authors.forename: R J
authors.initials: RJ
authors.lastname: Capone
authors.forename: D G
authors.initials: DG
authors.lastname: Wyse
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000517:prevention & control; D016700:Encainide / Q000627:therapeutic use; D005260:Female; D005424:Flecainide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D016293:Moricizine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality* / Q000503:physiopathology; D016019:Survival Analysis; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000889:Anti-Arrhythmia Agents; D016293:Moricizine; D005424:Flecainide; D016700:Encainide